---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071839"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:53:36.364750+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q1 net loss $27.5M; appoints Tony Gibney as CFO; Phase 3 CoMpass enrollment may complete by end 2025

## Summary
- Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.
- Cash and marketable securities $128.0M as of March 31, 2025; runway into second half of 2026.
- Appointed Tony Gibney as Chief Financial and Business Officer effective May 13, 2025; he brings 30+ years biotech and investment banking experience.
- Phase 3 CoMpass trial in early-stage choroidal melanoma actively enrolling; enrollment may complete as early as end 2025.
- First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC; initial data at 3 months expected by year-end 2025.

## SEC filing metadata
- accession: 0000950170-25-071839
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/aura-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071839
- JSON: https://secwatch.observer/filing/0000950170-25-071839.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071839.txt

## Key facts
- Executive change
  Anthony Gibney was appointed as Chief Financial and Business Officer at Aura Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial and Business Officer
  source text: Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm
- Executive change
  Amy Elazzouzi changed role as Senior Vice President, Finance at Aura Biosciences, Inc..
  - Action: ceased serving as principal financial officer
  - Role: Senior Vice President, Finance
  source text: Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.